Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) had its price objective raised by equities researchers at TD Securities from $20.00 to $27.00 in a research note issued to investors on Friday, January 5th. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. TD Securities’ price objective would suggest a potential upside of 13.26% from the company’s previous close.
A number of other equities analysts have also weighed in on the company. Wells Fargo & Co reiterated an “underperform” rating and set a $8.00 price objective on shares of Valeant Pharmaceuticals Intl in a research note on Saturday, September 30th. Cantor Fitzgerald reiterated a “buy” rating and set a $23.00 price objective on shares of Valeant Pharmaceuticals Intl in a research note on Thursday, September 28th. Vetr upgraded Valeant Pharmaceuticals Intl from a “strong sell” rating to a “sell” rating and set a $12.46 price objective for the company in a research note on Thursday, September 28th. Piper Jaffray Companies restated a “sell” rating and set a $14.00 target price on shares of Valeant Pharmaceuticals Intl in a research report on Sunday, September 17th. Finally, HC Wainwright restated a “hold” rating and set a $17.00 target price on shares of Valeant Pharmaceuticals Intl in a research report on Monday, September 18th. Six analysts have rated the stock with a sell rating, ten have assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $18.20.
Valeant Pharmaceuticals Intl (VRX) traded up $0.03 during trading on Friday, hitting $23.84. The stock had a trading volume of 10,194,862 shares, compared to its average volume of 20,720,000. The firm has a market cap of $8,300.00, a PE ratio of 6.11, a price-to-earnings-growth ratio of 0.72 and a beta of -0.22. The company has a debt-to-equity ratio of 4.84, a current ratio of 1.26 and a quick ratio of 1.03. Valeant Pharmaceuticals Intl has a 52-week low of $8.31 and a 52-week high of $24.43.
In other news, Director John Paulson purchased 344,216 shares of Valeant Pharmaceuticals Intl stock in a transaction dated Thursday, November 16th. The shares were purchased at an average price of $14.40 per share, with a total value of $4,956,710.40. Following the transaction, the director now owns 94,559 shares in the company, valued at $1,361,649.60. The purchase was disclosed in a document filed with the SEC, which is available through this link. 5.87% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Riggs Asset Managment Co. Inc. increased its position in shares of Valeant Pharmaceuticals Intl by 118.2% during the third quarter. Riggs Asset Managment Co. Inc. now owns 8,330 shares of the specialty pharmaceutical company’s stock worth $119,000 after acquiring an additional 4,512 shares during the period. Cetera Investment Advisers purchased a new stake in shares of Valeant Pharmaceuticals Intl during the second quarter worth $192,000. Harbour Capital Advisors LLC purchased a new stake in shares of Valeant Pharmaceuticals Intl during the third quarter worth $224,000. American Century Companies Inc. acquired a new position in shares of Valeant Pharmaceuticals Intl during the third quarter worth $238,000. Finally, Moors & Cabot Inc. grew its stake in shares of Valeant Pharmaceuticals Intl by 32.3% during the second quarter. Moors & Cabot Inc. now owns 15,275 shares of the specialty pharmaceutical company’s stock worth $267,000 after purchasing an additional 3,725 shares in the last quarter. 49.45% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/13/valeant-pharmaceuticals-intl-vrx-price-target-increased-to-27-00-by-analysts-at-td-securities.html.
Valeant Pharmaceuticals Intl Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.